TeleTracking releases Capacity Management Suite system version 2.3

TeleTracking Technologies today announced release of  its Capacity Management Suite system version 2.3, which allows users to control core patient flow automation functions from an Apple® iPad®, streamline sign-on protocol for faster login, and speed responses to unexpected spills.

The Capacity Management Suite™ system version 2.3, the latest version of the industry's leading patient flow software, is available immediately to all current clients on TeleTracking's XT platform.  Some of the key enhancements include:

  • Apple® iPad® access to TeleTracking's PreAdmitTracking® and PatientTracking Portal applications, enabling caregivers to  remotely review and update TeleTracking's popular electronic bedboard® and perform several other commonly used functions.
  • A Single Sign-On feature which permits faster authenticated login to the Capacity Management Suite™ system, saving time and increasing efficiency for users.
  • A "Spill Clean" feature through TeleTracking's BedTracking® application which alerts EVS personnel about time-consuming spills and provides data on clean-up performance.
  • Notification Enhancements which allow users to create and send group notifications from within the Capacity Management Suite™ system.

"We are constantly listening to our clients and the market," said Jason Baim, vice president of product management.  "This release reflects our commitment to supporting the latest in mobile technology with iPad® compatibility and to innovation which improves all hospital operations critical to patient throughput, efficiency and performance measurement."

"With over 1850 solutions at more than 850 acute care hospitals, including many of the largest and most advanced in the world, " Baim said, "we have the largest client base in the patient flow industry, allowing us to always stay at the forefront of changing client needs."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine and Qilu Pharmaceutical partner to develop AI-designed cardiometabolic drugs